The Phase 3 Trials of Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Author: Sang Hyoung PARK ¹
Author Information

1. Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. shpark78@amc.seoul.kr
Publication Type:Brief Communication
MeSH: Crohn Disease*; Ustekinumab*
From:The Korean Journal of Gastroenterology 2017;69(1):90-91
CountryRepublic of Korea
Language:Korean
Abstract: No abstract available.